Brazil's BNDES lends Eurofarma $51.9M for opioid-alternative drugs
What's the deal? Brazil's development bank BNDES has approved US$72.9M in debt financing for EurofarmaDealroom has a profile for this one. Try Dealroom →, the Brazilian pharmaceutical company, to fund research into innovative pain treatments. The money comes from the BNDES Mais Inovação program and backs projects at the firm's headquarters and research centre in Itapevi, São Paulo.
What's the endgame? The financing targets drugs with the potential to replace opioids, plus an antibiotic to combat resistant microorganisms. It also funds clinical trials, new drug combinations for depressive disorder and Alzheimer's, and seven imported research machines with no domestic equivalent.
Why now? The deal sits within a wider BNDES push to finance pharmaceutical R&D, alongside recent approvals of US$76.2M for Althaia and support for an EMSDealroom has a profile for this one. Try Dealroom → facility in Manaus. Eurofarma separately secured US$127.9M from the bank in 2024 for roughly 200 R&D and generic projects, suggesting this round is targeted rather than a replacement.
At US$72.9M, the round ranks around the 91st percentile among debt deals for health companies in Brazil, based on a sample of 5,866 rounds — a sizeable commitment in its category.
What could go wrong? The non-opioid pain candidates and the antibiotic remain in development and are not guaranteed to reach patients. That leaves the public-health payoff uncertain, even as the funding is confirmed.
The signal: BNDES is pressing a sustained drive to build domestic pharmaceutical innovation, having approved US$2.99B in health-sector financing since 2023. Bank president Aloizio Mercadante said that money has already contributed to 672 new medicines, vaccines, active ingredients, and medical devices, with the aim "to expand the capacity of national industry to meet the population's needs" (translated from Portuguese). Eurofarma's focus on pain and resistance treatments gives this round a clearer rationale than routine capacity expansion.
Read more: valor.globo.com
Image credit: Governo do Estado de São Paulo
